Rosiñol Dachs, LauraHebraud, BenjaminOriol, AlbertColin, Anne LaurèneRíos Tamayo, RafaelHulin, CyrilleBlanchard, María JesúsCaillot, DenisSureda, AnnaHernández, Miguel TeodoroArnulf, BertrandMateos, Maria VictoriaMacro, MargaretSan Miguel, JesúsBelhadj, KarimLahuerta, Juan JoséGarelik, M. BrigidBladé, J. (Joan)Moreau, Philippe2024-01-162024-01-162023-11-022234-943Xhttps://hdl.handle.net/2445/205802ObjectiveProviding the most efficacious frontline treatment for newly diagnosed multiple myeloma (NDMM) is critical for patient outcomes. No direct comparisons have been made between bortezomib + lenalidomide + dexamethasone (VRD) and bortezomib + thalidomide + dexamethasone (VTD) induction regimens in transplant-eligible NDMM.MethodsAn integrated analysis was performed using patient data from four trials meeting prespecified eligibility criteria: two using VRD (PETHEMA GEM2012 and IFM 2009) and two using VTD (PETHEMA GEM2005 and IFM 2013-04).ResultsThe primary endpoint was met, with VRD demonstrating a noninferior rate of at least very good partial response (>= VGPR) after induction vs VTD. GEM comparison demonstrated improvement in the >= VGPR rate after induction for VRD vs VTD (66.3% vs 51.2%; P = .00281) that increased after transplant (74.4% vs 53.5%). Undetectable minimal residual disease rates post induction (46.7% vs 34.9%) and post transplant (62.4% vs 47.3%) support the benefit of VRD vs VTD. Treatment-emergent adverse events leading to study and/or treatment discontinuation were less frequent with VRD (3%, GEM2012; 6%, IFM 2009) vs VTD (11%, IFM 2013-04).ConclusionThese results supported the benefit of VRD over VTD for induction in transplant-eligible patients with NDMM. The trials included are registered with ClinicalTrials.gov (NCT01916252, NCT01191060, NCT00461747, and NCT01971658).12 p.application/pdfengcc by (c) Rosiñol, Laura et al., 2023http://creativecommons.org/licenses/by/3.0/es/Mieloma múltipleTerapèuticaMultiple myelomaTherapeuticsinfo:eu-repo/semantics/article2023-12-13info:eu-repo/semantics/openAccess38023148